13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • FASTRACK II

    Acronym: 

    FASTRACK II

    ACTRN/NCT /ethics: 

    ACTRN12615001181594

    Scientific title: 

    Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II)

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase II Tumour Stream Kidney
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Kidney
    Cancer Stage
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Surgery is the standard treatment for primary kidney cancer, however, in some cases surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) and all participants will receive this radiotherapy technique. The aim of the study is to test the ability of this technique to control the cancer within the kidney for those people where surgery is not an option, as well as to examine the side effects of the treatment, including how it may affect your kidney’s function.

    Lay Summary

    Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II)

    Sponsor / Cooperative group

    Trans Tasman Radiation Oncology Group (TROG)

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Dr Braden Higgs Recruiting